<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Strides Pharma Science Limited — News on 6ix</title>
<link>https://6ix.com/company/strides-pharma-science-limited</link>
<description>Latest news and press releases for Strides Pharma Science Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 22:13:33 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/strides-pharma-science-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68364f3478dffbe2df154d3c.webp</url>
<title>Strides Pharma Science Limited</title>
<link>https://6ix.com/company/strides-pharma-science-limited</link>
</image>
<item>
<title>Press Release Mar 17 2026</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-mar-17-2026-8</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-mar-17-2026-8</guid>
<pubDate>Tue, 17 Mar 2026 22:13:33 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz".</description>
</item>
<item>
<title>Press Release (Revised) Feb 05 2026</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-revised-feb-05-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-revised-feb-05-2026-1</guid>
<pubDate>Thu, 05 Feb 2026 13:49:20 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a revised press release dated February 05, 2026, titled "Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility at Chestnut Ridge, New YorkInspection included Drug Device Combinations covering our recent filing in Nasal Sprays domain".</description>
</item>
<item>
<title>Press Release Feb 05 2026</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-feb-05-2026-48</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-feb-05-2026-48</guid>
<pubDate>Thu, 05 Feb 2026 13:31:28 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility at Chestnut Ridge, New YorkInspection included Drug Device Combinations covering our recent filling in Nasal Sprays domain".</description>
</item>
<item>
<title>Press Release Jan 30 2026</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-jan-30-2026-40</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-jan-30-2026-40</guid>
<pubDate>Fri, 30 Jan 2026 17:53:56 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated January 30, 2026, titled "Strides Continues to Deliver Exceptional Performance With Highest Ever Quarterly EBITDA of &#8377;2,359m in Q3FY26".</description>
</item>
<item>
<title>Press Release Oct 31 2025</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-oct-31-2025-26</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-oct-31-2025-26</guid>
<pubDate>Fri, 31 Oct 2025 17:00:55 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 31, 2025, titled "Strides Delivers a Robust Q2FY26 with Highest Ever Quarterly EPSQ2FY26 Operational PAT at &#8377;1,403m and EPS at &#8377;15.2, Grew 84% YoY".</description>
</item>
<item>
<title>Press Release Oct 17 2025</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-oct-17-2025-45</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-oct-17-2025-45</guid>
<pubDate>Fri, 17 Oct 2025 19:26:18 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 17, 2025, titled "Strides and Incepta Partner to Expand Women s Health Access with WHO-Prequalified Contraceptive".</description>
</item>
<item>
<title>Kenox Enters into Strategic Product Development Partnership with Strides</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/kenox-enters-into-strategic-product-development-partnership-with-strides</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/kenox-enters-into-strategic-product-development-partnership-with-strides</guid>
<pubDate>Tue, 09 Sep 2025 16:47:00 GMT</pubDate>
<description>Strides Pharma Science Ltd today announced that its step-down, wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. ("Kenox"), a fast-growing contract development and manufacturing company specializing in Orally Inhaled and Nasal Drug Products (OINDPs).</description>
</item>
<item>
<title>Press Release Sep 08 2025</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-sep-08-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-sep-08-2025-10</guid>
<pubDate>Mon, 08 Sep 2025 22:25:48 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated September 08, 2025, titled "Strides Enters into a Strategic Product Development Partnership with Kenox to Expand Nasal Spray Portfolio for the US Market".</description>
</item>
<item>
<title>Press Release Jul 29 2025</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-jul-29-2025-29</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-jul-29-2025-29</guid>
<pubDate>Tue, 29 Jul 2025 16:39:06 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated July 29, 2025, titled "Strides Delivers a Strong Q1FY26 with &#8377;11,197m Revenue, &#8377;2,181m EBITDA, and &#8377;1,140m Operational PAT".</description>
</item>
<item>
<title>Press Release May 22 2025</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-may-22-2025-33</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-may-22-2025-33</guid>
<pubDate>Thu, 22 May 2025 17:40:26 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated May 22, 2025, titled "Strides Delivers strong FY25 Results, Exceeding Outlook Across All Metrics. ".</description>
</item>
<item>
<title>Press Release Apr 30 2025</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-apr-30-2025-25</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-apr-30-2025-25</guid>
<pubDate>Wed, 30 Apr 2025 19:10:10 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg".</description>
</item>
<item>
<title>Press Release Jan 30 2025</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-jan-30-2025-40</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-jan-30-2025-40</guid>
<pubDate>Thu, 30 Jan 2025 18:42:20 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated January 30, 2025, titled "Press release on Q3 financial results".</description>
</item>
<item>
<title>Press Release Jan 20 2025</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-jan-20-2025-25</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-jan-20-2025-25</guid>
<pubDate>Mon, 20 Jan 2025 19:59:40 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated January 20, 2025, titled "Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets, 125 mg /250 mg, Expanding the Existing OTC Portfolio.".</description>
</item>
<item>
<title>Press Release Oct 24 2024</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-oct-24-2024-38</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-oct-24-2024-38</guid>
<pubDate>Thu, 24 Oct 2024 17:27:14 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 24, 2024, titled "Outcome of Board meeting - Financial Results and Earnings presentation".</description>
</item>
<item>
<title>Press Release Oct 16 2024</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-oct-16-2024-15</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-oct-16-2024-15</guid>
<pubDate>Wed, 16 Oct 2024 12:06:49 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 16, 2024, titled "OneSource, the Group s Spec Pharm CDMO, receives equity commitments of INR 8,010 mn (USD 95 mn) from marquee investors at a pre-money equity valuation of USD 1.65 bn".</description>
</item>
<item>
<title>Press Release Sep 16 2024</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-sep-16-2024-12</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-sep-16-2024-12</guid>
<pubDate>Mon, 16 Sep 2024 19:06:17 GMT</pubDate>
<description>Strides receives USFDA approval for Fluoxetine Tabs 60 mg; Expanding the Product s Availability Across Strengths.</description>
</item>
<item>
<title>Press Release Sep 11 2024</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-sep-11-2024-18</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-sep-11-2024-18</guid>
<pubDate>Wed, 11 Sep 2024 14:47:18 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated September 11, 2024, titled "Strides announces approval from Equity Shareholders and Secured Creditors for creation of OneSource India s first Specialty Pharma CDMO.".</description>
</item>
<item>
<title>Press Release Sep 06 2024</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-sep-06-2024-9</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-sep-06-2024-9</guid>
<pubDate>Fri, 06 Sep 2024 14:09:49 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated September 06, 2024, titled "Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg".</description>
</item>
<item>
<title>Press Release May 22 2024</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-may-22-2024-31</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-may-22-2024-31</guid>
<pubDate>Wed, 22 May 2024 17:50:26 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated May 22, 2024, titled "Outcome of Board Meeting ".</description>
</item>
<item>
<title>Press Release May 10 2024</title>
<link>https://6ix.com/company/strides-pharma-science-limited/news/press-release-may-10-2024-21</link>
<guid isPermaLink="true">https://6ix.com/company/strides-pharma-science-limited/news/press-release-may-10-2024-21</guid>
<pubDate>Fri, 10 May 2024 16:23:04 GMT</pubDate>
<description>Strides Pharma Science Limited has informed the Exchange regarding a press release dated May 10, 2024, titled "Strides receives USFDA approval for Sevelamer Carbonate Tablets, 800 mg".</description>
</item>
</channel>
</rss>